nach oben

Der Nervenarzt

Erschienen in:

01.09.2015 | Leitthema

Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen

Allgemeine Prinzipien

verfasst von: PD Dr. T. Messer, F.-G. Pajonk, M.J. Müller

Erschienen in: Der Nervenarzt | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Pharmakotherapie psychiatrischer Notfallpatienten wird wesentlich von der Akuität, dem Notfallort, der diagnostischen Einschätzung und dem besonderen pharmakologischen Anforderungsprofil der eingesetzten Medikamente bestimmt. Da es keine spezifischen Medikamente gibt, erfolgt die Behandlung syndromal. Hierfür stehen vorrangig Antipsychotika und Benzodiazepine zur Verfügung. Der vorliegende Beitrag gibt einen Überblick über den aktuellen Stand der Behandlungsoptionen für die wichtigsten psychiatrischen Notfallsyndrome, nämlich Unruhezustände, Delir, Katatonie und Stupor, Angst und Panik sowie medikamentös-induzierte Notfälle.

TREC Collaborative Group (2003) Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 327:708–713CrossRef

Ables AZ, Nagubilli R (2010) Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 81:1139–1142PubMed

Alexander J, Tharyan P, Adams C et al (2004) Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry 185:63–69CrossRefPubMed

Allen MH, Currier GW (2004) Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 26:42–49CrossRefPubMed

Asadollahi S, Heidari K, Hatamabadi H et al (2015) Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol 30:142–150CrossRefPubMed

Babington PW, Spiegel DR (2007) Treatment of catatonia with olanzapine and amantadine. Psychosomatics 48:534–536CrossRefPubMed

Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP (2011) Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr 33:30–39CrossRefPubMed

Barak Y, Mazeh D, Plopski I, Baruch Y (2006) Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry 14:629–633CrossRefPubMed

Barbee JG, Mancuso DM, Freed CR, Todorov AA (1992) Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 149:506–510CrossRefPubMed

10.

Bartels SJ, Horn SD, Smout RJ et al (2003) Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use. Am J Geriatr Psychiatry 11:231–238CrossRefPubMed

11.

Battaglia J (2005) Pharmacological management of acute agitation. Drugs 65:1207–1222CrossRefPubMed

12.

Battaglia J, Moss S, Rush J et al (1997) Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15:335–340CrossRefPubMed

13.

Belgamwar RB, Fenton M (2005) Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev:CD003729

14.

Belvederi Murri M, Guaglianone A, Bugliani M et al (2015) Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 15:45–62CrossRef

15.

Bieniek SA, Ownby RL, Penalver A, Dominguez RA (1998) A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 18:57–62PubMed

16.

Breier A, Meehan K, Birkett M et al (2002) A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59:441–448CrossRefPubMed

17.

Carroll BT, Goforth HW, Thomas C et al (2007) Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 19:406–412CrossRefPubMed

18.

Cavallazzi R, Saad M, Marik PE (2012) Delirium in the ICU: an overview: Ann Intensive Care 2:49

19.

Chan EW, Taylor DM, Knott JC et al (2013) Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med 61:72–81CrossRefPubMed

20.

Citrome L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 68:1876–1885CrossRefPubMed

21.

Citrome L (2012) Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract 66:318–325CrossRefPubMed

22.

Citrome L, Volavka J, Czobor P et al (2006) Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 67:638–642CrossRefPubMed

23.

Crowner ML, Peric G, Stepcic F, Lee S (2005) Assailant and victim behaviors immediately preceding inpatient assault. Psychiatr Q 76:243–256CrossRefPubMed

24.

Currier GW, Chou JC, Feifel D et al (2004) Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 65:386–394CrossRefPubMed

25.

De Fruyt J, Demyttenaere K (2004) Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. Eur Psychiatry 19:243–249CrossRef

26.

Di Salvo TG, O’Gara PT (1995) Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 18:285–290CrossRef

27.

Dorevitch A, Katz N, Zemishlany Z et al (1999) Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 156:142–144CrossRefPubMed

28.

Dosi R, Ambaliya A, Joshi H, Patell R (2014) Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014

29.

Foster S, Kessel J, Berman ME, Simpson GM (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12:175–179CrossRefPubMed

30.

Frucht SJ (2014) Treatment of movement disorder emergencies. Neurotherapeutics 11:208–212PubMedCentralCrossRefPubMed

31.

Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF (1989) Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation: Am J Psychiatry 146:1598–1601

32.

Gillman PK (2010) Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 25:1780–1790CrossRefPubMed

33.

Goedhard LE, Stolker JJ, Heerdink ER et al (2006) Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry 67:1013–1024CrossRefPubMed

34.

Gortney JS, Fagan A, Kissack JC (2009) Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 43:785–791CrossRefPubMed

35.

Grover S, Kumar V, Chakrabarti S (2011) Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. J Psychosom Res 71:277–281CrossRefPubMed

36.

Han CS, Kim YK (2004) A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45:297–301CrossRefPubMed

37.

Hatta K, Takahashi T, Nakamura H et al (2001) The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol 21:257–261CrossRefPubMed

38.

Hovens JE, Dries PJ, Melman CT et al (2005) Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol 19:51–57CrossRefPubMed

39.

Huband N, Ferriter M, Nathan R, Jones H (2010) Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev:CD003499

40.

Huf G, Alexander J, Allen MH, Raveendran NS (2009) Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev:CD005146

41.

Jones RM, Arlidge J, Gillham R et al (2011) Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 198:93–98CrossRefPubMed

42.

Kim SW, Yoo JA, Lee SY et al (2010) Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 25:298–302CrossRefPubMed

43.

Kinon BJ, Stauffer VL, Kollack-Walker S et al (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 28:601–607CrossRefPubMed

44.

Kirino E (2010) Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clin Schizophr Relat Psychoses 4:185–188CrossRefPubMed

45.

Knott JC, Taylor DM, Castle DJ (2006) Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med 47:61–67CrossRefPubMed

46.

Kropp S, Andreis C, te Wildt B et al (2007) Characteristics of psychiatric patients in the accident and emergency department (ED). Psychiatr Prax 34:72–75CrossRefPubMed

47.

Kwentus J, Riesenberg RA, Marandi M et al (2012) Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 14:31–40CrossRefPubMed

48.

Lee KU, Won WY, Lee HK et al (2005) Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. Int Clin Psychopharmacol 20:311–314CrossRefPubMed

49.

Lesem MD, Tran-Johnson TK, Riesenberg RA et al (2011) Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 198:51–58CrossRefPubMed

50.

Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev:CD005594

51.

Lonergan E, Luxenberg J (2009) Valproate preparations for agitation in dementia. Cochrane Database Syst Rev:CD003945

52.

Marco CA, Vaughan J (2005) Emergency management of agitation in schizophrenia. Am J Emerg Med 23:767–776CrossRefPubMed

53.

Moscovich M, Novak FT, Fernandes AF et al (2011) Neuroleptic malignant syndrome. Arq Neuropsiquiatr 69:751–755CrossRefPubMed

54.

Munhoz RP, Moscovich M, Araujo PD, Teive HA (2012) Movement disorders emergencies: a review. Arq Neuropsiquiatr 70:453–461CrossRefPubMed

55.

Musshoff F, Doberentz E, Madea B (2013) Lethal neuroleptic malignant syndrome due to amisulpride. Forensic Sci Med Pathol 9:218–220CrossRefPubMed

56.

Owen C, Tarantello C, Jones M, Tennant C (1998) Violence and aggression in psychiatric units. Psychiatr Serv 49:1452–1457CrossRefPubMed

57.

Pajonk FG, Schmitt P, Biedler A et al (2008) Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. Gen Hosp Psychiatry 30:360–366CrossRefPubMed

58.

Pascual JC, Madre M, Soler J et al (2006b) Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 39:117–118CrossRefPubMed

59.

Patra BN, Khandelwal SK, Sood M (2013) Olanzapine induced neuroleptic malignant syndrome. Indian J Pharmacol 45:98–99PubMedCentralCrossRefPubMed

60.

Pelland C, Trudel JF (2009) Atypical antipsychotic efficacy and safety in managing delirium: a systematic review and critical analysis. Psychol Neuropsychiatr Vieil 7:109–119PubMed

61.

Peralta V, Campos MS, Jalon EG de, Cuesta MJ (2010) DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res 118:168–175CrossRefPubMed

62.

Perry PJ, Wilborn CA (2012) Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 24:155–162PubMed

63.

Powell G, Caan W, Crowe M (1994) What events precede violent incidents in psychiatric hospitals? Br J Psychiatry 165:107–112CrossRefPubMed

64.

Pratts M, Citrome L, Grant W et al (2014) A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 130:61–68CrossRefPubMed

65.

Puffer E, Messer T, Pajonk FG (2012) Psychiatric care in emergency departments. Anaesthesist 61:215–223CrossRefPubMed

66.

Raveendran NS, Tharyan P, Alexander J, Adams CE (2007) Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 335:865PubMedCentralCrossRefPubMed

67.

Rocca P, Villari V, Bogetto F (2006) Managing the aggressive and violent patient in the psychiatric emergency. Prog Neuropsychopharmacol Biol Psychiatry 30:586–598CrossRefPubMed

68.

Rortgen D, Schaumberg A, Skorning M et al (2011) Stocked medications in emergency physician-based medical services in Germany. Reality and requirements according to guidelines. Anaesthesist 60:312–324CrossRefPubMed

69.

Satterthwaite TD, Wolf DH, Rosenheck RA et al (2008) A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69:1869–1879PubMedCentralCrossRefPubMed

70.

Schwerthöffer D, Beuys D, Hamann J et al (2015) Versorgung psychiatrischer Notfälle in psychiatrischen Kliniken in Deutschland. Psychiatr Prax. DOI 10.1055/s-0034-1387644

71.

Seitz DP, Adunuri N, Gill SS et al (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev:CD008191

72.

Skrobik YK, Bergeron N, Dumont M, Gottfried SB (2004) Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 30:444–449CrossRefPubMed

73.

Strawn JR, Keck PE Jr, Caroff SN (2007) Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876CrossRefPubMed

74.

Tardiff K, Sweillam A (1982) Assaultive behavior among chronic inpatients. Am J Psychiatry 139:212–215CrossRefPubMed

75.

Trollor JN, Chen X, Chitty K, Sachdev PS (2012) Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 201:52–56CrossRefPubMed

76.

Trollor JN, Sachdev PS (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 33:650–659CrossRefPubMed

77.

Uguz F, Sonmez EO (2013) Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen Hosp Psychiatry 35:327CrossRefPubMed

78.

Vieweg WV, Wood MA, Fernandez A et al (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26:997–1012CrossRefPubMed

79.

Villari V, Rocca P, Fonzo V et al (2008) Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 32:405–413CrossRefPubMed

80.

Wagstaff AJ, Easton J, Scott LJ (2005) Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19:147–164CrossRefPubMed

81.

Wang HR, Woo YS, Bahk WM (2013) Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci 67:323–331CrossRefPubMed

82.

Wang Y, He R, Zhang H (2012) Case report on clozapine-associated neuroleptic malignant syndrome. Shanghai Arch Psychiatry 24:116–117PubMedCentralPubMed

83.

Wilson MP, MacDonald K, Vilke GM, Feifel D (2012) A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med 43:790–797CrossRefPubMed

84.

Wilson MP, Minassian A, Bahramzi M et al (2014) Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department. J Emerg Med 46:808–813CrossRefPubMed

85.

Wilson MP, Pepper D, Currier GW et al (2012) The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 13:26–34PubMedCentralCrossRefPubMed

86.

Wright P, Birkett M, David SR et al (2001) Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158:1149–1151CrossRefPubMed

87.

Zeller SL, Rhoades RW (2010) Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther 32:403–425CrossRefPubMed

88.

Zisselman MH, Jaffe RL (2010) ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 167:127–132CrossRefPubMed

Titel: Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen
Allgemeine Prinzipien
verfasst von: PD Dr. T. Messer
F.-G. Pajonk
M.J. Müller
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Der Nervenarzt / Ausgabe 9/2015
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-014-4148-x

Neu in den Fachgebieten Neurologie und Psychiatrie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen

Allgemeine Prinzipien

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

Zur Situation der Notfall- und Akutpsychiatrie in Deutschland

Erregungszustände

Mitteilungen der DGPPN 9/2015

Moral oder Doppelmoral?

Antidepressiva verhindern nicht Suizidversuche oder Suizide

Hilfesuchverhalten und Behandlungswege von Patienten mit Zwangsstörungen

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet